Digital Trials Digest, our quarterly newsletter
One of the keys to optimizing ePRO is deploying artificial intelligence (AI) to support human participants and clinical teams.
The unique challenges associated with women’s health, and women as a cohort, make clinical research in this sector especially difficult. DCTs are helping to tackle the obstacles.
eConsent can mitigate these shortcomings by providing flexibility and engagement that empower patients with information and sponsors with data integrity.
Diversity in clinical trials is a scientific imperative, a moral and ethical necessity—and a longstanding challenge in clinical research. DCTs are evolving the industry status quo.
Combining the ease of ePRO with expert rating—patient convenience with the objectivity of experts—facilitates more accurate data collection.
Expectations for the time it takes to complete a vaccine clinical trial have been radically raised by the mRNA vaccines’ successes.
Decentralized trials (DCTs) expand older adults’ access to trials, allowing them to participate at higher rates.
Digital transformation is reshaping nearly every industry, and clinical trials are no exception. As technology plays a bigger role in healthcare, patients are demanding more access to medical research. It’s not just patients who are asking for more: Medical professionals, researchers, and pharmaceutical companies all want to improve quality, efficiency, and access to clinical trials.
The use of real world data in clinical trials is a hot topic. Doctors, biotech and pharmaceutical companies alike point to the tremendous potential to leverage this data to improve health outcomes.
Virtual clinical trials aren’t just a buzzword—these research models are here to stay. In fact, the global market for virtual clinical trials is expected to reach $12.9 billion by 2030, according to Grand View Research.